


ID 214

Mailing address:
Françoise Van Bambeke
av. Mounier 73, B173.05
1200 Brussels – Belgium
francoise.vanbambeke@uclouvain.be

A. Anantharajah¹, E. Faure^{2,3}, J.M. Buyck¹, PM.Tulkens¹,
M.P. Mingeot-Leclercq¹, B. Guery^{2,3} and F. Van Bambeke¹

¹ Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium; ² Lille-2 University hospital, Lille, France, ³Host-Pathogen translational Research group *Pseudomonas aeruginosa*, Lille, France

INTRODUCTION and AIMS



T3SS is produced by *P. aeruginosa* (*P.a.*) and many other pathogenic Gram-negative bacteria. This system injects effector proteins into the cytosol of host cells. T3SS effectors cause a cell type-dependent cytotoxicity (ExoS and ExoU) [3] and prevent *P.a.* internalization (ExoS, ExoT and ExoY) ([1-2]). T3SS apparatus can also participate to cytotoxicity by delivering flagellin or rod proteins into the mammalian cytosol, which induces caspase-1 proteolysis via NLRP4 inflammasome activation. Active caspase-1 induces pyroptosis and release of inflammatory cytokines IL-1 β and IL-18 [4]. A role of inflammasome activation in *P.a.* pathogenicity was suggested, related to impairment of bacterial clearance [5].

We ran a systematic study to define the role of T3SS proteins in internalisation, cytotoxicity and inflammasome activation, using epithelial and phagocytic cells, and isogenic strains with specific deletions in T3SS genes.

METHODS

Strains: CHA (clinical isolate expressing T3SS), CHAΔExsA (deletion of T3SS regulon) CHAΔS, ΔT, ΔSTY (deletion of genes encoding ExoS or ExoT toxins, triple mutant), CHA ΔpopBD, ΔpcrV (deletion of genes encoding translocation apparatus); PA103 (cytotoxic strain expressing ExoU phospholipase).

Cells: human alveolar epithelial A549 cells; THP-1 monocytes

Cell viability: release of the cytosolic enzyme lactate dehydrogenase (LDH) in the culture medium after 7 h (A549 cells) or 5 h (THP-1 monocytes) of incubation. *P.a.* strains (10 bact./cell).

Inflammasome activation: IL-1 β release (ELISA); Caspase-1 activation (Western Blot)

Internalisation assay: bacteria were opsonised with human serum for 1 h and phagocytosis was initiated with 10 bact./cell for 5 h (A549 cells) or 2 h (THP-1 cells). Non-phagocytised bacteria were eliminated by gentamicin (1 h). Cells were washed and cell-associated CFU were counted.


	PA103	CHA	ΔS	ΔT	ΔSTY	ΔExsA	ΔpopBD	ΔpcrV
A549 epithelial cells	Internalization	-	+/-	+	++	+++	+++	+++
	Cytotoxicity	+++	++	-	++	-	-	-
	IL-1 β release	-	-	-	-	-	-	-
THP-1 monocytes	Internalization	+/-	+	++	++	+++	+++	+++
	Cytotoxicity	+++	+	+/-	++	+	-	-
	IL-1 β release	+	++	++	+++	-	-	-

- Internalisation was more efficient in phagocytic cells than in epithelial cells.
- In both cell types, internalisation rate was as follows: [ΔExsA, ΔpopBD, ΔpcrV, ΔSTY] > [ΔT, ΔS] > [CHA] > [PA103].
- Cytotoxicity was inversely correlated to internalisation ([ΔExsA, ΔpopBD, ΔpcrV] < [ΔS] < [ΔT] ≈ [CHA] < [PA103]) and of the same order of magnitude in both cell types, except for ASTY, which was more cytotoxic for THP-1 cells (56%) than for A549 cells (20%).
- Caspase-1 activation and IL-1 β release were induced by CHA, ΔS, ΔT, ΔSTY and to a lower extent PA103, but not by ΔExsA, ΔpopBD, ΔpcrV in THP-1 cells (not detected in A549 cells).

CONCLUSION

In A549 epithelial cells, toxicity is related to toxins injection (especially ExoS) in the cytosol, which also prevents internalisation. In THP-1 phagocytic cells, internalisation remains toxin-dependent while toxicity rather relies on the expression of translocation apparatus. Indeed, ΔSTY (not expressing toxins but still translocation apparatus) remains capable of activating NLRP4 inflammasome, a phagocyte-specific defence mechanism [6], which induces caspase-1 activation and IL-1 β maturation. PA103 toxicity remains mainly toxin-dependent, due to rapid membrane-disrupting effects of ExoU.

RESULTS



REFERENCES

- [1] Fleiszig SM *et al*, Infection & Immunity 1996 4(6):2288-94.
- [2] Hauser AR *et al*, Infection & Immunity 1998, 66(4):1413-20.
- [3] Vance RE *et al*, Infection & Immunity 2005;73(3):1706-10.
- [4] Miao EA and Warren SE, Journal of Clinical Immunology 2010; 30(4): 502-506
- [5] Cohen TS and Prince AS, Journal of Clinical Investigation 2013; 23(4):1630-7
- [6] Vinzing M *et al*, Journal of Immunology 2008;180(10):6808-15

ACKNOWLEDGMENTS

We thank M.C Cambier, K. Santos, and P. Muller for excellent technical assistance. We thank Pr. Toussaint (GREPI EA2938, Grenoble, France) for the kind gift of CHA. A. Anantharajah is doctoral fellow of the Belgian Fonds de la Recherche Scientifique (F.S.R.-FNRS). This work was supported by the Belgian Fonds de la Recherche Scientifique and the Interuniversity Attraction Poles Programme of the Belgian Science Policy Office.